TABLE 2.
Efficacy outcome variables.
| Variables | Baseline | 3 months | 6 months |
|---|---|---|---|
| Remission, complete and partial (N, %) | NA | NA | 7 (20%) |
| 24 h urine protein (g/d) | 10.15 (4.83, 13.57) | 6.02 (4.83, 11.24)a | 7.04 (4.43, 8.90)b |
| Albumin (g/L) | 21.40 (16.75, 25.00) | 24.80 (22.05, 29.90)a | 30.55 (24.97, 33.27)b |
| Serum creatinine (µmol/L) | 152.00 (134.50, 232.50) | 136.00 (126.00, 214.50) | 99.50 (75.25, 140.250)b |
| eGFR (ml/min/1.73 m2) | 41.12 (26.53, 51.41) | 47.85 (30.54, 53.86) | 78.29 (50.15, 101.55)b |
| anti-PLA2R-Ab–positive patients (N, %) | 34 (97.14%) | 25 (71.42%)a | 24 (68.57%)b |
| anti-PLA2R-Ab–depleted patients (N, %) | NA | 9/34 (26.47%) | 10/34 (29.41%) |
| anti- PLA2R-Ab titer (RU/mL) | 59.20 (17.70, 187.50) | 8.60 (0.00, 42.50)a | 7.70 (5.72, 16.72)b |
| CD19, per mm | 179.00 (85.00, 272.50) | 1.00 (0.00, 3.00)a | 25.50 (3.75, 57.75) |
| CD4, per mm | 893.00 (561.00, 1,095.00) | 718.00 (460.50, 908.50) | 816.00 (417.00, 1,031.25) |
| Post hoc composite end point at 6 months | NA | NA | 16 (45.71%) |
Data presented as number (percentage) or median (first-third interquartile range).a or b Stands for p < 0.05 vs. baseline. BP, blood pressure; eGFR, estimated glomerular filtration rate; anti- PLA2R-Ab, anti-phospholipase A2 receptor antibody; CD, cluster of differentiation; Complete and partial remissions were defined according to 2021 KDIGO criteria on the basis of proteinuria; composite end point was defined as reduction of proteinuria >50% and increase of serum albumin >30%.